Financials data is unavailable for this security.
View more
Year on year Teva Pharmaceutical Industries Ltd grew revenues 6.17% from 14.93bn to 15.85bn. Additionally the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as percentages of sales). These changes narrowed profitability losses from -2.45bn to -559.00m.
| Gross margin | 51.01% |
|---|---|
| Net profit margin | -7.46% |
| Operating margin | 2.67% |
| Return on assets | -2.99% |
|---|---|
| Return on equity | -15.28% |
| Return on investment | -4.34% |
More ▼
Cash flow in USDView more
In 2023, Teva Pharmaceutical Industries Ltd increased its cash reserves by 13.87%, or 393.00m. The company earned 1.37bn from its operations for a Cash Flow Margin of 8.63%. In addition the company generated 968.00m cash from investing, though they paid out 1.91bn more in financing than they received.
| Cash flow per share | -0.6437 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 19.81 |
|---|---|
| Tangible book value per share | -48.40 |
More ▼
Balance sheet in USDView more
| Current ratio | 0.8925 |
|---|---|
| Quick ratio | 0.6056 |
| Total debt/total equity | 3.13 |
|---|---|
| Total debt/total capital | 0.7483 |
More ▼
